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Abstract 
Background: HIV infected children experience a range of hematological complications which show marked 
improvement within 6 months of initiating anti-retroviral therapy. The Objectives of the study was to describe the 
changes in hematological indices of HIV-1 infected children following 6 months of treatment with first line antiretrovi-
ral drugs (ARVs) regimen.
Methods: A retrospective study was conducted between September and November 2008. During this period medi-
cal records of children attending Comprehensive Care Clinic at Kenyatta National hospital were reviewed daily. HIV 
infected children aged 5–144 months were enrolled if they had received antiretroviral drugs for at least 6 months with 
available and complete laboratory results.
Results: Medical records of 337 children meeting enrollment criteria were included in the study. The median age was 
63 months with equal male to female ratio. Following 6 months of HAART, prevalence of anemia (Hemoglobin (Hb) 
<10 g/dl) declined significantly from 35.9 to 16.6 % a nearly 50 % reduction in the risk of anemia RR = 0.56 [(95 % CI 
0.44, 0.70) p < 0.001]. There was significant increase in Hb, mean corpuscular volume (MCV), mean corpuscular hemo-
globin (MCH) and platelets above the baseline measurements (p < 0.0001) and a significant decline in total white 
blood cell counts >11,000 cell/mm3 but a none significant decrease in red blood cells (RBC). Pre-HAART, World Health 
Organization (WHO) stage 3 and 4 was associated with a ten-fold increased likelihood of anemia. Chronic malnutrition 
was associated with anemia but not wasting and immunologic staging of disease.
Conclusion: Hematological abnormalities changed significantly within 6 months of antiretroviral therapy with signifi-
cant increase in hemoglobin level, MCV, MCH and platelet and decrease in WBC and RBC.
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Background
Hematological complications of human deficiency virus 
infection (HIV) which include cytopenias of all major cell 
lines were recognized shortly after the first description 
of AIDS cases [1]. Unexplained anemia defined as hemo-
globin of less than 8 g/dl, neutropenia <1000 cells/mm3 
or thrombocytopenia less than 30,000 platelets/mm3 
persisting for more than one month are currently classi-
fied as WHO stage 3 disease [2]. Anemia, the most com-
mon abnormality causes chronic fatigue, affects cognitive 
function and influences the choice of ART and opportun-
istic infection (OI) medications and has been noted to be 
the commonest hematological abnormalities in adults in 
Kenya [3, 4].
In published literature prevalence of anemia among 
HIV-1 infected children varies from 16 to 94 % and this 
increases with advancing stage of HIV disease but varies 
with sex, age and the definition of anemia used [5–10]. 
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In a meta-analysis of over 2000 HIV infected children, 
the prevalence of mild [hemoglobin (Hb) 10–12.0] and 
moderate anemia (Hb 8.0–9.9) was 22–94 % and 3–82 % 
respectively [10]. The prevalence of mild and moderate 
anemia in Western settings ranged from 22 to 94 % and 
11 to 82  % respectively while in tropical settings it was 
50–91 % for mild anemia and 3–38 % for moderate ane-
mia [10]. Neutropenia is present in approximately 10  % 
of patients with early, asymptomatic HIV infection, and 
more than half in individuals with more advanced HIV-
related immunodeficiency [5, 6, 11]. Thrombocytope-
nia which is frequently asymptomatic occurs in 20 % to 
33 % of paediatric patients with HIV with the prevalence 
increasing with duration of illness and development of 
Aids [5, 6, 9, 11, 12].
The most important cause of anemia in HIV infected 
children is insufficient production of erythrocytes caused 
by ineffective erythropoiesis, reduced erythropoietin 
production, associated infections, neoplasia, medica-
tions and micronutrient deficiencies. Iron deficiency is 
the most common cause of nutritional anemia globally. 
There is significant geographical overlap of areas of the 
world where iron deficiency anemia (IDA) and paediatric 
HIV are distributed. The causes of anemia in the commu-
nity investigated are Multifactorial with iron deficiency 
prevalence being high due to nutritional deficiency and 
helminthes. In a study in western Kenya by Footer et al. 
anemia was found to be prevalent and was present in 
71.8  % of children [13]. Factors commonly thought to 
be associated with anemia were found to be widespread, 
including malaria parasitemia (32.5  %), iron deficiency 
(34.6 %), vitamin A deficiency (16.3 %), stunting (29.6 %), 
wasting (3.3 %), HbS (17.1 %), HbSS (1.6 %), heterozygous 
α-thalassemia (38.5  %), and homozygous α-thalassemia 
(9.6 %) [13]. This is similar to WHO finding that Iron defi-
ciency is the most common cause of anemia of micronu-
trient-related etiology worldwide, affecting about 50 % of 
women and children in developing countries and about 
25 % of men [14]. Another prominent cause of reduced 
production of all hematological elements in patients with 
HIV infection is the common use of multiple medica-
tions, many of which may cause marrow suppression e.g. 
Zidovudine (AZT) and other nucleoside analogues can 
cause a dose-dependent neutropenia [15]. Other medica-
tions causing hematological abnormalities include gan-
ciclovir, trimethoprim-sulphamethoxazole, pentamidine 
and dapsone [9].
Studies have confirmed the ability of HAART to correct 
or improve the anemia and other hematological param-
eters of HIV infection. In a study of 6725 HIV-infected 
patients from across Europe, Microft and colleagues 
found that the use of Stavudine, zidovudine and Lami-
vudine was statistically associated with improvement in 
hemoglobin levels [16]. When used for longer periods 
of time, HAART was associated with greater likelihood 
of correcting anemia. Microft et  al. found that, 65.5  % 
of patients were anemic before the use of HAART, 53 % 
were anemic after 6  months of HAART (p  <  0.0001), 
and 46 % were anemic after 12 months of HAART [16]. 
Huang et al. found an increase in Hb occurring with mean 
increase from baseline of 13.9 to 14.1 g/dl after 3 months 
of treatment and this was not statistically significant [17]. 
After 6 months Hb had increased to 14.6 g/dl (p < 0.01), 
9 months 14.6 g/dl (p = 0.001) and at 12 months mean of 
14.3 g/dl (p < 0.01) [17]. In a different study in children 
in Zambia, the mean hemoglobin increased from 10.3 g/
dl at baseline to a mean of 11.3 g/dl (CI 95 % 11.2–11.4 g/
dl) after 6 months of HAART [18]. In a study in Burkina-
Faso hematological changes after 6 months of AZT based 
HAART showed anemia at 51.4 vs 80.3 % at baseline with 
P  =  0.0001 [19]. Other hematological parameter noted 
to markedly increase after HAART was MCV. Huang 
et  al. found an increase of MCV following treatment 
from baseline of 5.5 to 98.9 fl p < 0.1 at 3 months, 105.5 fl 
(p < 0.001) at 6 months, 106 fl at 9 months (p < 0.001) and 
102.8 fl p < 0.001 at 12 months [17].
The prevalence of hematological abnormalities among 
children treated with ART in routine care settings in 
Kenya have not yet been described even though the first 
line antiretroviral regimen to date includes drugs with 
significant hematological adverse events such as zido-
vudine. The objective of the study was to describe the 
changes in hemoglobin levels, red cell morphology, white 
blood cells and platelets in HIV-1 infected children aged 
5–144 months following 6 months of highly active antiret-
roviral therapy at the comprehensive care clinic of KNH.
Results
Baseline characteristics of the study participants
A total of 337 children were recruited into the study, 
among them 53.4  % female and 46.6  % male giv-
ing a female to male ratio of 1.1:1, and a median age of 
63  months (range of 5–144  months) as shown in the 
Table  1. Almost all children in the study population 
received Cotrimoxazole 323 (98.8 %) and the remaining 
4 (1.2 %) received dapsone. One eighty nine (56.4 %) pre-
sented in WHO clinical stage III at ART initiation while 
48 (14.3 %) were in WHO clinical stage IV. The number/
proportion of children in stages I and II were 77 (23 %) 
and 21(6.3  %) respectively. Eighty four children (25  %) 
were started on iron supplements during the initiation of 
antiretroviral drugs. Zidovudine-Lamivudine backbone 
(AZT/3TC) based regimens were the most frequently 
used first line ART protocol and used by 291 (86.3  %) 
children in combination with efavirenz (EFV), nevirapine 
(NVP) or abacavir (ABC).
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Hematological parameters pre and six months post HAART 
initiation
Hemoglobin level
At baseline 35.9 % study participants had a Hb <10.0 g/dl 
compared to 16.6 % after 6 months of ART, a statistically 
significant reduction in risk of anemia RR = 0.56 [(95 % 
CI 0.44, 077) p < 0.0001] as shown in Table 2. The median 
Hb at baseline was 10.6 and 11.5  g/dl before and after 
6 months of ART, a significant median increase in Hb of 
0.9 g/dl (p < 0.0001) as shown in Table 3. The median Hb 
level of 203 (75  %) children who were not on iron sup-
plements at baseline and after 6  months of ART was 
11 g/dl, and 11.8 g/dl respectively a statistical significant 
change (p < 0.0001). Eighty four children (25 %) who were 
receiving iron supplements had a baseline median Hb of 
9.25 g/dl and increased to 11 g/dl following 6 months of 
treatment, a significant median increase of Hb 1.75 g/dl 
(p < 0.0001). Female were reported to have higher hemo-
globin levels at the baseline 51.9 % compared to the males 
40.3  % although there were more males with moderate 
anemia (37  %) compared to female 23.1  %. Following 
6 months of HAART majority of children of both sexes 
had hemoglobin levels within the normal ranges with 
73.7 % being female and 68.5 % males. Children who ini-
tially were reported with severe anemia had reduced to 
1.3 % from 4.5 % of female with no male reported to have 
severe anemia.
Mean corpuscular volume (MCV)
At baseline 31  % of the study participants had a mean 
corpuscular volume (MCV) below the 70 fl compared to 
8.3 % at end of 6 months of ART treatment, a 63 % decline 
in the risk RR  =  0.37 [(95  % CI 0.27,0.52) P  <  0.0001] 
as shown in Table  2. The median corpuscular volume 
at baseline was 75.9  fl and increased to 89.2  fl after 
6  months of HAART, a statistically significant median 
increase by 13.2 fl of corpuscular volume (p < 0.0001) as 
show in Table 3.
Table 1 Baseline demographic characteristics of the study 
participants
Variable Frequency (n = 337) number, 
(%), or median
Female 179 (53.4 %)




Weight for age Z score
 SD > −2 130 (39 %)
 SD −3 to −2 95 (28 %)
 SD < −3 112 (33 %)
Weight for height Z score
 SD > −2 229 (88 %)
 SD −3 to −2 22 (6.5 %)
 SD < −3 15 (4.4 %)
Height for age Z score
 SD > −2 85 (25 %)
 SD −3 to −2 53 (16 %)
 SD < −3 198 (59 %)
CD4 count median (1QR) 456 (171.0–753)
CD4 percent median (1QR) 9.9 (5.0–14.0)
Table 2 Changes in the prevalence of abnormal haematological parameters
Characteristic N = 337 Baseline no (%) 6 months after initiation  
of HAART no (%)
Relative risk (95 % CI) P value
Hb <10 g/dl 121 (35.9) 56 (16.6) 0.56 (0.44, 0.70) <0.0001
MCV <70 fl 104 (31.0) 28 (8.3) 0.37 (0.27, 0.52) <0.0001
MCH <24 pg 154 (46.7) 49 (14.6) 0.45 (0.35, 0.59) <0.0001
Platelets <150,000 67 (20.0) 22 (6.5) 0.46 (0.32, 0.66) <0.0001
WBC <11,000 33 (10.0) 21 (6.2) 0.76 (0.54, 1.08) 0.09
Granulocytes <1000 22 (6.5) 52 (16) 1.48 (1.25, 1.75) <0.0001
Table 3 Changes in haemoglobin levels, MCV, MCH and RBC
Characteristic N = 337 Baseline median no (%) or (IQR) 6 months after initiation  
of HAART no (IQR)
Median change P value
Hb (g/dl) 10.6 (9.4–11.6) 11.5 (10.5–12.4) 0.9 <0.0001
MCV (fl) 75.9 (68.0–82.3) 89.2 (80.0–97.6) 13.2 <0.0001
MCH (pg) 24.3 (21.5–27.5) 29.1 (25.8–32.1) 4.9 <0.0001
RBC (m/mm3) 4.3 (3.8–5.0) 4.0 (3.6–4.3) 0.3 0.27
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Mean corpuscular hemoglobin (MCH)
The prevalence of low mean corpuscular hemoglobin 
(MCH) before and after 6  months of ARVs was 46.7   
and 14.6  % respectively. The relative risk of low MCH 
was RR =  0.45 [(95  % CI 0.35, 0.59) p  <  0.0001], a sta-
tistically significant reduction. At baseline median MCH 
was 24.3  pg and increased to 29.0  pg after 6  months of 
ART a statistically significant median increase of 4.9 pg 
(p < 0.0001) as shown in Table 3.
Red blood cells
At baseline the median number of red cells was 4.3 mil-
lion/mm3 and declined to 4.0 million/mm3 after 6 months 
of highly active antiretroviral therapy. The median change 
in RBC was 0.4 million cells/mm3 and this was not statis-
tically significant (p = 0.27) as shown in Table 3.
HAART regimen combination and hemoglobin level
Children with Stavudine combination had higher hemo-
globin increments as compared to zidovudine or other 
combinations as shown in Table  4. There was statistical 
significant increase in mean Hb level in both zidovudine 
and Stavudine combinations but the mean hemoglobin 
change was more with Stavudine combinations at 1.83 g/
dl for Stavudine combination and 0.7 g/dl for zidovudine 
combinations. Indications of choice of regimen to use 
were based on baseline hemoglobin levels. Majority of 
children with Hb of above10 g/dl were started on zidovu-
dine combination while Children with low Hb of less than 
10 g/dl were started on Stavudine or other combinations.
Platelets
Proportion of children with platelet counts below 
150,000/mm3 before and after 6 months of ARV was 20 
and 6.5 % respectively, a significant reduction in the risk 
of thrombocytopenia RR  =  0.46 [(95  % CI 0.32, 0.66) 
p < 0.0001] as shown in Table 3. At baseline the median 
platelets counts were 255  ×  103/mm3 (IQR 159  ×  103/
mm3–352 × 103/mm3), and which increased to a median 
of 279  ×  103/mm3 (IQR 224  ×  103/mm3–349  ×  103/
mm3) following 6 months of ART as shown in Fig. 1.
White blood cells
Before ART initiation 10  % of the children had ele-
vated white blood cell counts above 11,000 cell/mm3 
compared to 6.2 % after 6 months of ARV initiation. The 
proportion of children with elevated total WBC thus 
decreased with ART RR =  0.76 [(0.54, 1.08) P =  0.09] 
a non-significant decline. Overall the median total 
WBC count at baseline was 9.4  ×  103/mm3 which 
declined significantly to a median of 6.7  ×  103  cells/
mm3 (p  <  0.0001). At baseline only 6.5  % of the study 
participants had granulocyte counts of less than 1000 
cells/mm3 compared to 16  % after 6  months of ARVs, 
a statistically significant increased likelihood of hav-
ing low granulocyte counts RR  =  1.48 [(1.25, 1.75), 
P  <  0.0001]. The total granulocyte count declined sig-
nificantly following 6  months of ART from a median 
of 2.8 × 103/mm3–2 × 103/mm3 (IQR 1.4 × 103/mm3–
5.1 ×  103/mm3) (p  <  0.0001) as shown in Table  5. The 
median lymphocyte count was of 5.2  ×  103  cell/mm3 
before treatment initiation and declined significantly to 
4.2 × 103 cell/mm3, (p < 0.0001) following 6 months of 
ART.
Factors associated with low baseline hemoglobin level
In a stratified analysis the 216 (64.1 %) and 121 (35.9 %) 
children with Hb above and below 10  g/dl respectively 
were compared to determine demographic and clini-
cal characteristics associated with anemia. Children in 
WHO stage 3 and 4 were more likely to have Hb of less 
than or equal to 10 g/dl compared to children in WHO 
stage 1 and 2 OR = 10.6 (95 % CI 3.64, 36.3) (P < 0.001). 
Children with WAZ greater than −2 SD had signifi-
cantly reduced likelihood of having Hb of less than 10g/
dl OR = 0.62 [(95 % CI 0.38, 1.01) P = 0.04] as shown in 
Table 6.
Discussion
In this study we report increase in most hematological 
indices following 6  months of ART in children. Follow-
ing 6  months of treatment with HAART, hematological 
reconstitution occurred progressively for all blood line-
ages except RBC, total WBC, granulocytes and total 
lymphocytes counts. The positive effect of HAART is 
probably due to the reduction in viral load, decreased 
destruction of mature hematopoietic cells of multiple lin-
eages and an improvement in the blunted erythropoietin 
response [11]. HAART could also have lead to decreased 
incidences of opportunistic infections [17].
Table 4 Haemoglobin level changes and HAART combination
Drug regimen Number Mean Hb at  
baseline
Mean Hb after  
6 months
Mean change P Value
Zidovudine combination 293 10.7 11.4 0.7 0.000
Stavudine combination 38 9.77 11.6 1.83 0.01
Other combinations 6 7.68 11.2 3.52 0.864
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The median increase in Hb levels of 0.9  g/dl was well 
within the range of the 0.8–1.0  g/dl in published stud-
ies. Microft et al. in Europe and Huang et al. reported an 
increase from 13.9 to 14.6  g/dl a statistical association 
between the level of Hb and duration of use of HAART 
was also found [16, 17]. In children, Bolton-Moore et al. 
found that for children with baseline mean Hb of 10.3 g/
dl, it had increased to 11.3 g/dl after6 months of HAART 
almost similar to our study [18]. In another study in Bur-
kina-Faso, Nacoulma et al. found that after 6 months of 
AZT based HAART anemia prevalence had reduced [19]. 
Drug regimen was noted to have a big influence on the 
increments in hemoglobin level with Stavudine combi-
nation having a much higher increment as compared to 
zidovudine combination findings similar to other studies 
[20].
In this study children who received iron supplements 
were noted to have higher hemoglobin increments this 
is similar to the findings in Malawi where iron supple-
mentation in HIV infected children increased hemo-
globin levels and reduced the prevalence of anemia by 
40  % but iron was noted to increase the risk of malaria 
[21]. Identification of children to be given iron in this 
study was based on low baseline hemoglobin levels as 
recommended by WHO on targeted iron supplemen-
tation for children at risk of anemia and iron deficient 
Fig. 1 Comparison of platelet levels at baseline and after 6 months of treatment
Table 5 Changes in WBC, Granulocytes and lymphocytes following six months of HAART
Characteristic N = 337 Baseline Median (IQR) 6 months after of HAART  
Median (IQR)
Median change P value
WBC (×103/mm3) 8.7 (IQR 6.2–11.5) 6.7 (IQR 5.2–8.5) 2.0 <0.0001
Granulocytes × 103/mm3 2.8 (IQR 1.8–4.3) 2.0 (IQR 1.4–2.9) 0.8 <0.0001
Lymphocytes × 103/mm3 4.8 (2.9–6.7) 4.2 (3.0–5.1) 0.6 <0.0001








CD4 (median) 9.0 10.8 0.2
WHO <0.0001
 Stage 1 
and 2
76 (35.2 %) 4 (8.2 %) 1
 Stage 3 
and 4
140 (64.8 %) 80 (81.8 %) 10.6 (3.64, 
36.3)
WHZ 0.58
 <−2 26 (12.0 %) 17 (14.2 %) 1
 >−2 190 (88.0 %) 103 (85.8 %) 0.83 (0.41, 
1.68)
WAZ 0.04
 <−2 124 (57.4 %) 83 (68.6 %) 1
 >−2 92 (42.6 %) 38 (31.4 %) 0.62 (0.38, 
1.01)
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[14]. Children who received these drugs had markedly 
reduced hemoglobin level at baseline. Some of these 
children were also provided with food supplement and 
nutritional education and this could have contributed 
to marked increase. The study was not able to identify 
whether those given iron supplements had higher risk of 
sepsis due to retrospective nature of the study.
When we compared the mean corpuscular volume at 
baseline of 75.9 fl with that after 6 months of treatment of 
89.2 fl, we found an increase in median change that was 
higher than the findings of Huang et al. in adults of 95.5 fl 
at baseline to 105.5 fl following 6 months of HAART [17]. 
The increase could have been due to nutritional modifi-
cation offered, iron supplements or antiretroviral drugs. 
Macrocytosis was found to have occurred after treat-
ment and this could be attributed to the effect of mainly 
zidovudine as this has been found in other studies [22]. 
A striking and discrepant observation was that the circu-
lating RBC counts decreased significantly following six 
months of HAART despite increase in hemoglobin levels 
and mean corpuscular volume. This finding is similar to 
the findings of Huang et al. and may be associated with 
defect in the production of erythrocytes from erythroid 
progenitor cells leading to the generation of fewer but 
larger cells [17].
Total white blood cells were found to decrease signifi-
cantly from 8.7 × 103 mm3 to 6.7 × 103 mm3 in this study 
probably because at the time of enrollment, the children 
might have had intercurrent acute or chronic infections 
causing leucocytosis and following treatment and ini-
tiation of HAART the levels were seen to have decreased 
and this could have been due to the antiretroviral drugs 
improving immunity leading to less infections. Similar 
findings were reported by Nacoulma et al. in adults after 
six months of AZT based HAART of 2.27 × 103 mm3 at 
baseline compared to 1.9 ×  103  mm3 after 6  months of 
HAART [19]. The finding in this study contrast some 
studies which reported significant increase in WBC fol-
lowing treatment with Huang et  al. reporting a mean 
increase of 0.8 (p  <  0.001) [17]. In this study, there was 
a statistical significant increase in platelets levels from 
255 × 103 mm3 to 279 × 103 mm3 similar to findings by 
Huang et al. in adults [17].
In this study the first line regimens as recommended by 
the Ministry of Health of both zidovudine based and Sta-
vudine based were shown to lead to a significant change 
in hematological parameters similar to the findings in 
various other studies [17, 18]. Moyle G et  al. in their 
study also assessed the mean decreased in hemoglobin 
level comparing various regimens after treatment which 
we were unable to do due the small number of patients 
that were started on Stavudine based and protease inhibi-
tor based regimens [4].
Conclusion
The findings of this study suggest that Antiretrovi-
ral drugs lead to a significant change in hematologi-
cal parameters with a positive change of hemoglobin 
levels, MCV, MCH and platelet and decrease in 
total WBC, granulocytes lymphocytes and RBC. 
This indicates that zidovudine based regimens may 
safely be used even in setting with limited laboratory 
monitoring.
Methods
This retrospective cohort study was carried out at Ken-
yatta National Hospital comprehensive care centre 
between September and November 2008. Children were 
enrolled into the study if they were age 5–144  months, 
confirmed to be HIV positive by rapid tests for those aged 
over 18  months and PCR DNA for those aged less than 
18  months, attending the Kenyatta National Hospital 
comprehensive care center. They also had to have received 
the first line ART according to the Kenyan Ministry of 
Health guidelines without change of treatment for at least 
six months with available complete medical records and 
parents/guardians provided informed consent. Standard 
study tools were used to abstract data from the medical 
records of enrolled children and included demographic, 
clinical and laboratory characteristics. The laboratory 
data had been analyzed by University of Nairobi Paedi-
atric laboratory which undertakes laboratory procedures 
relating to the comprehensive care clinic. It uses a semi 
automated hematology analyzer MS4 and is a GCLP cer-
tified (Good Clinical Laboratory Practices) with external 
quality assurance. There is computerized data for all chil-
dren attending the clinic who are on HAART and it also 
details of the regimen the children is on and when started. 
Using ART number in the data base and patients appoint-
ment number we were able to identify the patients’ files. 
Files were retrieved as the clients came for review in 
their monthly clinic that runs daily from Monday to Fri-
day. Pre and 6-month post ART estimates of, absolute 
CD4, CD4%, hemoglobin level, total white blood cells 
count, absolute lymphocyte counts, granulocyte counts, 
and platelets counts were recorded in an abstract form. 
In addition information was obtained regarding use of 
all medications including prophylactic medications, iron 
supplementation, multivitamins, and HAART regimens. 
Ethical clearance to conduct the study was obtained from 
the department of Pediatrics and Child Health and the 
KNH ethical review Committee.
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Statistical methods
Data entry and analysis were done using SPSS version 
16.0. The weight for height Z scores (WHZ), height for 
age Z scores (HAZ) and weight for age Z scores (WAZ) 
were computed using the nutrition software of Epi Info 
3.2 Baseline hematological parameters were compared 
to those obtained after 6 months of HAART using Pear-
son Chi square test to compare categorical variables. 
Wilcoxon paired t-test for non parametric variables 
was used to determine the difference in baseline hema-
tological parameters and parameters after 6  months of 
HAART for parameters. Differences in associations and 
relationships were taken as significant where P was less 
than 0.05.
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